The first quarter of 2017 brought yet more disappointing sales figures for Amgen Inc.'s Repathaand Sanofi/Regeneron Pharmaceuticals Inc.'s Praluent, but the sponsors are hopeful for better uptake of the PCSK9 inhibitors through improved reimbursement policies on the back of new outcomes data.
Amgen reported worldwide sales of just $49m for Repatha (evolocumab) in the first quarter of 2017, which was actually down from $58m in the fourth quarter of 2016 and well under analyst expectations of $72m
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?